Beijing Minhai Biotechnology Co., Ltd.

beijing minhai biotechnology co.,ltd.is a modern biotechnology enterprise specialized in vaccine r&d;, production and distribution. minhai’s mission is to provide safe, stable and affordable vaccines; increase immunization coverage, reduce the incidence of infectious disease and mortality; protect human health. minhai was founded in june 2004, with a registered capital of 200 million rmb, at no.35, simiao road, bio-medicine industry park in daxing district, beijing, which has a leading r&d; center and a modern vaccine manufacturing site composed of over 60,000 m2 gmp compliant workshops, equipped with advanced large-scale bacteria vaccine production line and virus vaccine production line. until 2015, there are three commercialized vaccine products in china, including hib conjugate vaccine, mr vaccine and dtap-hib vaccine. dtap-hib vaccine, which is independently developed by minhai, is the first domestic quatri-valent vaccine. there are over 20 vaccines in minhai’s pipeline (from pre-c